Benny Amore, PhD

Benny assists clients with their development programs as an expert in A2-Ai’s clinical pharmacology group, specializing in therapies for oncology and cardiovascular disease. Most recently, at Esperion Therapeutics Benny supported the registrations and post-marketing requirements for the lipid-lowering therapies NEXLETOL and NEXLIZET.

Benny received his BS in Chemistry from Michigan State University, and his PhD in Pharmaceutics and Drug Metabolism under the supervision of Dr. John Slattery at the University of Washington. Prior to Esperion, he supported the BLA submission of enfortumab vedotin (PADCEV) for the treatment of patients with urothelial cancer, as well as the clinical development of multiple ADC, small and large molecule targeted therapies in oncology while at Seattle Genetics and Amgen. He also spent time dedicated to early discovery and preclinical development for candidates in inflammation, neurodegeneration, cardiovascular and infectious disease at Amgen, Pfizer and Pharmacia.